 |
 |
|
 |
 |
Comments on Paper and Primary News |
 |
  |
| |
Comment by: Roberta Diaz Brinton, ARF Advisor
|
 |
 |
Submitted 23 March 2010
| Permalink
|
Posted 23 March 2010
|
 |
 |
I recommend this paper
I suggest reading the excellent Alzforum news article by Tom Fagan on our findings regarding the efficacy of allopregnanolone to reverse neurogenic and cognitive deficits in the 3xTgAD male mouse in PNAS and hyperphosphorylated tau in neural progenitor cells reported by Orly Lazarov and colleagues. View all comments by Roberta Diaz Brinton
|
 |

|
| |
Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice
Comment by: Felix Hernandez
|
 |
 |
Submitted 23 March 2010
| Permalink
|
Posted 23 March 2010
|
 |
 |
We have previously published that doublecortin positive cells also express hyperphosphorylated tau (Fuster-Matanzo et al., 2009). Thus, we demonstrated that new neurons generated in the subgranular zone express tau in a hyperphosphorylated form. Phospho-tau expression colocalized with doublecortin but not with glial fibrillary acidic protein, Ki67 or calbindin. The same was observed in the subventricular zone. Tau knockout mice did not show a significant decrease in the number of doublecortin-positive cells, although a deficit in migration was observed. These findings suggest that tau phosphorylation in doublecortin-positive cells is involved in normal migration of new neurons.
References: Fuster-Matanzo A, de Barreda EG, Dawson HN, Vitek MP, Avila J, Hernández F. Function of tau protein in adult newborn neurons. FEBS Lett. 2009 583(18):3063-8. Abstract
View all comments by Felix Hernandez
|
 |

|
| |
Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice
Comment by: J. Lucy Boyd
|
 |
 |
Submitted 24 March 2010
| Permalink
|
Posted 24 March 2010
|
 |
 |
I recommend this paper
|
 |

|
| |
Primary News: Early Casualty, Neurogenesis Cripples Cognition in AD Mice
Comment by: Thomas Bayer, Oliver Wirths
|
 |
 |
Submitted 8 April 2010
| Permalink
|
Posted 8 April 2010
|
 |
 |
Whether or not physical activity and/or enriched environment could have a potential therapeutic effect in patients with Alzheimer disease (AD) is usually assessed in transgenic mouse models. There is no doubt that in wild-type mice, both physical activity and enriched environment lead to increased neurogenesis in some brain areas, e.g., the dentate gyrus. In contrast, the situation is much less clear in APP transgenic mouse models.
In a recent study, we analyzed neurogenesis in APP/PS1KI mice and quantified the number of doublecortin (DCX)-positive neurons in the subgranular zone of the dentate gyrus (Cotel et al., 2010). Already at the age of two months, a significantly reduced number of DCX-positive neurons were detected in APP/PS1KI mice compared to age-matched wild-type mice. This is the time point when the first amyloid plaques become apparent. In good agreement with a previous study (Faure et al., 2009), neurogenesis was almost completely absent by the age of six months. Interestingly, this loss of neurogenesis could not be modified by keeping the mice in an enriched...
Read more
Whether or not physical activity and/or enriched environment could have a potential therapeutic effect in patients with Alzheimer disease (AD) is usually assessed in transgenic mouse models. There is no doubt that in wild-type mice, both physical activity and enriched environment lead to increased neurogenesis in some brain areas, e.g., the dentate gyrus. In contrast, the situation is much less clear in APP transgenic mouse models.
In a recent study, we analyzed neurogenesis in APP/PS1KI mice and quantified the number of doublecortin (DCX)-positive neurons in the subgranular zone of the dentate gyrus (Cotel et al., 2010). Already at the age of two months, a significantly reduced number of DCX-positive neurons were detected in APP/PS1KI mice compared to age-matched wild-type mice. This is the time point when the first amyloid plaques become apparent. In good agreement with a previous study (Faure et al., 2009), neurogenesis was almost completely absent by the age of six months. Interestingly, this loss of neurogenesis could not be modified by keeping the mice in an enriched environment for a four-month period (from two to six months), although a significant increase in the number of DCX-positive neurons was detected in wild-type mice, underscoring the validity of the enrichment paradigm. Moreover, neuron loss in the CA1 region of the hippocampus of six-month-old APP/PS1KI mice (Breyhan et al., 2009) was not ameliorated by four months of enriched housing.
It is difficult to draw clear-cut conclusions for the human situation as environmental enrichment produced variable outcomes, probably due to differences in the AD mouse models that have been previously studied. The APP/PS1KI model represents a model for mild to severe AD. It shows early behavioral deficits starting at two months of age with fast deterioration. Therefore, our data might suggest that physical activity and enriched environment may only be beneficial in patients with mild cognitive impairment (or even earlier, before symptoms appear) and not in patients with early AD.
References: Cotel M.C., Jawhar S, Christensen D.Z., Bayer T.A., Wirths O. (2010). Environmental enrichment fails to rescue memory deficits, neuron loss and neurogenesis in APP/PS1KI mice. Neurobiology of Aging. Abstract
Faure A., Verret L., Bozon B., El Tannir El Tayara N., Ly M., Kober F., Dhenain M., Rampon C., Delatour B. (2009). Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer’s disease. Neurobiology of Aging. Abstract
Breyhan H., Wirths O., Duan K., Marcello A., Rettig J., Bayer T.A. (2009). APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathologica, 117 (6): 677-685. Abstract
View all comments by Thomas Bayer
View all comments by Oliver Wirths
|
 |
 |
| |
Submit a Comment on this Paper |
 |
 |
 |
 |
| |
 |
 |
| |
REAGENTS/MATERIAL:
Immunohistochemistry: Brain sections were incubated with
monoclonal anti-BrdU (Novus).
For identifying the phenotype of the newly formed BrdU-positive cells, adjacent sections were incubated overnight with the following primary antibodies:
rat monoclonal anti-BrdU (BU1/75) (AdB Serotec),
rabbit anti-GFAP (DAKO),
mouse monoclonal anti-NeuN (A60) (Chemicon MIllipore),
goat anti-Doublecortin (Santa Cruz Biotechnology).
For evaluating AD pathology development, sections were incubated with
mouse monoclonal anti-Amyloid beta (6E10) (Signet Covance).
Western Blot: Protein extracts from mouse hippocampus and cortex
were separated by SDS gel. After transfer, PVDF membrane was plotted with
mouse monoclonal anti-proliferating cell nuclear antigen PCNA (PC10) (Zymed Invitrogen),
rabbit anti-CDC2/p34 (Novus Biologicals),
mouse monoclonal anti-Amyloid beta (6E10) (Signet),
rabbit anti-Amyloid beta 1-42 (Chemicon Millipore),
mouse monoclonal anti-human tau PHF (AT8) (Pierce Thermo Scientific) and
mouse monoclonal anti-human tau PHF (HT7) (Pierce Thermo Scientific).
|
|
|
 |